Trial · NCT00645099
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to End Point in the Triglycerides (TG) to High Density Lipoprotein (HDL) Ratio (TG:HDL Ratio) | Paliperidone ER | -0.08 | Standard Deviation 1.10 | Ratio | |
| Change From Baseline to End Point in the Triglycerides (TG) to High Density Lipoprotein (HDL) Ratio (TG:HDL Ratio) | Olanzapine | 0.42 | Standard Deviation 1.19 | Ratio | |
| Change From Baseline to End Point in Triglycerides | Paliperidone ER | -0.01 | Standard Deviation 0.77 | mmol/L | |
| Change From Baseline to End Point in Triglycerides | Olanzapine | 0.36 | Standard Deviation 0.96 | mmol/L | |
| Change From Baseline to End Point in High Density Lipoprotein | Paliperidone ER | 0.01 | Standard Deviation 0.25 | mmol/L | |
| Change From Baseline to End Point in High Density Lipoprotein | Olanzapine | -0.04 | Standard Deviation 0.24 | mmol/L | |
| Change From Baseline to End Point in Total Cholesterol | Paliperidone ER | 0.0263 | Standard Deviation 0.7841 | mmol/L | |
| Change From Baseline to End Point in Total Cholesterol | Olanzapine | 0.2886 | Standard Deviation 0.8493 | mmol/L | |
| Change From Baseline to End Point in Low Density Lipoprotein Cholesterol (Friedwald QT) | Paliperidone ER | -0.0029 | Standard Deviation 0.6726 | mmol/L | |
| Change From Baseline to End Point in Low Density Lipoprotein Cholesterol (Friedwald QT) | Olanzapine | 0.1892 | Standard Deviation 0.7361 | mmol/L | |
| Change From Baseline to End Point in Converted Insulin | Paliperidone ER | 2.7397 | Standard Deviation 89.9776 | pmol/L | |
| Change From Baseline to End Point in Converted Insulin | Olanzapine | 17.2327 | Standard Deviation 84.6255 | pmol/L | |
| Change From Baseline to End Point in Fasting Glucose | Paliperidone ER | -0.2071 | Standard Deviation 0.4953 | mmol/L | |
| Change From Baseline to End Point in Fasting Glucose | Olanzapine | 0.0769 | Standard Deviation 0.4781 | mmol/L | |
| Change From Baseline to End Point in Homeostatic Model Assessment of Beta-cell Function (HOMA-%B) | Paliperidone ER | -7.54 | Standard Deviation 85.91 | dimensionless | |
| Change From Baseline to End Point in Homeostatic Model Assessment of Beta-cell Function (HOMA-%B) | Olanzapine | 18.82 | Standard Deviation 147.63 | dimensionless | |
| Change From Baseline to End Point in Homeastatic Model Assessment of Insulin Resistance (HOMA-IR) | Paliperidone ER | 0.28 | Standard Deviation 5.39 | dimensionless | |
| Change From Baseline to End Point in Homeastatic Model Assessment of Insulin Resistance (HOMA-IR) | Olanzapine | 0.43 | Standard Deviation 5.37 | dimensionless | |
| Number of Patients Meeting the Criteria for Type 2 Diabetes Mellitus During Follow-up | Paliperidone ER | 21 | Participants | ||
| Number of Patients Meeting the Criteria for Type 2 Diabetes Mellitus During Follow-up | Olanzapine | 23 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00645099/results